Login:
 
Rees J. Weighing up the risks and benefits of androgen deprivation therapy. Practitioner 2014; 258 (1771): 5

Weighing up the risks and benefits of androgen deprivation therapy

22 May 2014Registered users

The cardiovascular risks of androgen deprivation therapy (ADT) mean that a definite decision should be made regarding risk versus benefit for all men receiving this treatment. For men with high-risk prostate cancer, however, the oncological benefits of ADT are likely to outweigh the cardiovascular risks. Men receiving ADT should be 'medically optimised' in terms of cardiovascular risk and advice from their GP on exercise and diet is essential. [With external links to the current evidence base]

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.

To buy this article (£25+tax) copy the article citation above and click Buy article